Strategic planning is a most critical aspect of managing a product or portfolio. Often there are gaps in the internal knowledge base to make important decisions. With our institutional knowledge of oncology, proprietary access to the largest global database of cancer treaters, and hundreds of oncology intelligence projects successfully delivered, we deliver insightful and useful answers on which you can immediately build your plan.
International pharmaceutical company, rapidly growing through expansion in targeted disease areas.
Challenge
Client wished to understand the current treatment paradigms in CML and the outlook for the near and long term for a portfolio investment decision. They had conducted desk research to understand the disease state, but they needed real, robust and actionable disease intelligence delivered quickly.
Approach
80 screened hematologists in 5 countries with a turnaround time of 2 weeks
Customized quantitative research followed by select qualitative insights
Consultative insights report
Unique Proposition MDOutlook
Immediate access to pre-qualified and profiled Hematologic Oncologists
Institutional knowledge of CML, driving timely development of survey instrument
System integration of panel, survey technology and data capture allows for timely accrual
Results
Actionable, relevant and deep insight into the CML treatment landscape
Quantification of current treatment approaches and direction of future developments
Assessment of clinical relevance of specific therapeutic characteristics
Value Delivered
2-Week project delivering in-depth competitive intelligence and market size modelling of current and future CML landscape. Input for “go/no-go” decision to expand portfolio in this area.
Client Feedback
This swiftly executed project provided insight that allowed us to make a quick decision based upon where the market was most likely heading. In hindsight, it was accurate about the situation as well.
To learn more about this case, to discuss your oncology intelligence needs, or to schedule a demo of our oncology intelligence portal, contact us at [email protected] or +1.404.496.4136.
MDOutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the fourth and final report for our 2016 series covering new data presented in Chicago.
This OncoPoll™ focuses on melanoma, with a little merkel cell carcinoma included for good measure. As with the entire melanoma therapy area for the past few years, it focuses of the use of the checkpoint inhibitors and BRAF + MEK inhibitors for the treatment of BRAF V600E/K-mutant melanoma.
Our most recent research from a global panel of active melanoma treaters reveals:
• Melanoma treaters in all locations continue to see updates and expansions about the use of the checkpoint inhibitors as very important clinical developments. Focus now is beginning to change towards combinations and use as initial treatment lines
• Physicians also recognize the utility and importance of targeted therapy for BRAF-mutant melanoma, especially now that longer-term data is becoming available
• Even though combinations of BRAF + MEK inhibitors will remain the primary 1st line treatment choice for BRAF-mutant melanoma for more treaters than anything else, the use of checkpoint inhibitors in the front line will make strong inroads as the preferred option
MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!
MDOutlook presents the results from our innovative initiative of syndicated research gauging the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the third of four reports in our 2016 series covering clinical news presented in Chicago.
This OncoPoll™ focuses on non-prostate genitourinary cancers – both bladder and kidney cancers. It covers the expansion of the use of the checkpoint inhibitors into bladder cancer and renal cell carcinoma and the head-to-head comparison of cabozantinib vs. everolimus in the Meteor trial.
Our most recent research from a global panel of active genitourinary cancer treaters reveals:
• Oncologists see the use of the checkpoint inhibitors in bladder cancer as a very important clinical development, especially by those in the US. A slightly higher level of clinical importance to the checkpoint inhibitors are placed on their usage in 2nd+ lines of therapy, compared to the use of the 1st line
• The integration of the recently-approved atezolizumab into clinical practice has started off quickly, with 40% of US oncologists reporting their use of it in bladder cancer within the first month
• Oncologists are also enthusiastic about the use of nivolumab and cabozantinib as therapeutics for patients with RCC
• The interchangeability of checkpoint inhibitors is also explored in this report
MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!
MDOutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the second of four reports in our 2016 series covering news presented in Chicago.
This OncoPoll™ focuses on lung cancers, both non-small cell (NSCLC) and small cell (SCLC). It covers 2 abstracts about ALK+ NSCLC and 1 abstract in recurrent SCLC. Our most recent research from 146 global oncologists who are actively managing patients with lung cancer uncovers that:
Data presented from the J-ALEX trial examining the use of alectinib in the 1st line setting for ALK+ NSCLC is globally reported as clinically meaningful
The excitement is tempered somewhat, as most have some concerns since the data was from a single country. This makes the results of the global ALEX trial that much more eagerly awaited
The use of brigatinib in the 2nd line setting for ALK+ NSCLC was also assigned a relatively high level of clinical importance. This rating implies that it will be readily integrated into practices once it becomes commercially available
Oncologists are enthusiastic about the strategy of dual checkpoint inhibition for recurrent SCLC. Impressive levels of growth for both nivolumab alone and in combination with ipilimumab are expected in the very near future. Nivolumab is expected to be used in a majority of US recurrent SCLC patients over the next year
MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!
MDOutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the first report in our 2016 series covering new clinical data presented in Chicago.
This OncoPoll™ focuses on the gastrointestinal tumors, focusing on 4 abstracts in colorectal and pancreatic cancers. Our most recent research from 134 global oncologists managing GI cancer patients uncovers that:
• Data presented in 3 abstracts on primary tumor sidedness in metastatic colorectal cancer is reported as clinically meaningful.
• Changes in treatment selections will primarily occur only for left-sided tumors, with a 38% increase in the use of FOLFOX or FOLFIRI + cetuximab, with a 9% decrease in the use of bevacizumab in these patients
• Oncologists assign high importance to data presented on the addition of capecitabine to gemcitabine in the adjuvant setting for resected pancreatic cancer
• Gemcitabine + capecitabine (GEMCAP) is expected to become the standard of care in the adjuvant setting for resectable pancreatic cancer, with ~ half of all patients receiving it moving forward
• Integration of these results into clinical practice are going to happen in relatively short order, especially since agents are already widely available and in use
MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!
Before the 2016 ASCO Annual Meeting® started, we asked oncologists about which tracks they were most excited. With the annual neeting behind us, we followed up to find out which tracks actually delivered on that excitement. Included in our Post-Chicago OncoPoll™ were a few questions: “Did you attend this year’s annual meeting in Chicago?” and “About which therapy track(s) were you most excited?”.
MDOutlook® is pleased to share excerpts from this most recent MDOutlook OncoPoll™ series on the oncologists reactions to the data presented in Chicago.
OncoPoll™ Methodology
Primary research phase involved global survey to verified and validated medical, hematologic, surgical, and radiation oncologists within the proprietary MDOutlook® global cancer treater panel
Fielded: June 8th through 13th
Research via interactive web-based survey instruments, utilizing proven MDOutlook methodology and proprietary technology
Aided list of Annual Meeting tracks was provided from which to choose
Response: 132 oncologists
Key Conclusions: Overall Post-Meeting Reactions for 2016 Annual Meeting in Chicago
Overall, there was more excitement about the individual tracks before the meeting, than once the data were presented
Physicians are now most excited about the new data in metastatic NSCLC announced at the conference
Conclusions
The top mentioned track was metastatic NSCLC, with 39% of respondents choosing this as an area of excitement in the annual meeting
The next 5 tracks were tied for 2nd place, with 33-34% of respondents choosing these areas
Genitourinary (Nonprostate) Cancer caused the most excitement outside of the US, but only ranked 10th in the US
Conclusions
Looking specifically at those tracks selected by more than 30% of the respondents, one gets the overall impression that the level of excitement continues to be higher in the US than in other regions
Genitourinary (Nonprostate) Cancer is the exception, with the US oncologists far less enthusiasm than the ex-US physicians
Overall, the most excitement is with the US oncologists and Metastatic NSCLC, likely because of the J-ALEX data announcement
Conclusions
The pre-ASCO excitement was not sustained for most tracks
The greatest disappointment was with Breast Cancer – HER2/ER, with 13% fewer oncologists having post-conference excitement about the track than had anticipation for it
Genitourinary (Nonprostate) Cancer track produced the most positive difference in excitement after the conference than before
For More Information
We are conducting our annual series of OncoPolls to assess the immediate impact of the meeting on clinical practice. Please look for these reports to be published here in the near future. You can download a PDF copy of the report here.
To discuss your oncology intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!
With another meeting of the American Society of Clinical Oncology® behind us, the MDOutlook disease analyst team is set to launch our 8th annual OncoPoll™ series measuring the immediate clinical impact of new data presented at the 2016 Annual Meeting in Chicago.
The largest gathering of cancer treaters in the world (more than 37,000 professionals) saw a number of really interesting announcements. In addition, a great emphasis was placed on the need for intensified collaboration between cancer treaters, researchers, life sciences organizations and advocacy organizations.
Since our inception in 2008, MDOutlook has spearheaded this global collaboration and connecting those involved in the management of cancer in meaningful ways. We now have developed the largest panel of cancer treaters in the world (>95,000!) and offer unrivaled access to engage oncology-focused clinicians in targeted ways.
Watch this space for the updates from our OncoPoll™ research. The first reports will be available on this website later this month.
Almost all of the recent buzz in oncology is focused on the 2016 ASCO Annual Meeting®, which is starting this Friday in Chicago. In order to see how this information is being received by oncologists, we asked our panel of physicians a simple 2-question survey: “Are you planning to attend this year’s meeting in Chicago?” and “About which therapy track(s) are you most excited?”.
MDOutlook® are pleased to share excerpts from this most recent MDOutlook’s OncoPoll™ on the oncologists’ expectations leading into the 2016 Annual Meeting.
OncoPoll™ Methodology
Primary research phase involved global survey to verified and validated medical, hematologic, surgical, and radiation oncologists within the proprietary MDOutlook® global cancer treater panel
Fielded: Monday May 30th – June 1st, 2016
Research via interactive web-based survey instruments, utilizing proven MDOutlook methodology and proprietary technology
Aided list of meeting tracks was provided from which to choose
Response: 147 oncologists from 30 different countries
Key Conclusions: Overall Pre-Meeting Expectations for the 2016 ASCO Annual Meeting
Overall, there is no general consensus as to which therapy area(s) will be the hottest this year. None of the tracks were selected by more than 50% of the respondents
Physicians are most excited about the new data in breast cancer, with the two breast cancer tracks both being within the top 3 most selected by physicians
Conclusions
The top mentioned track was Breast – Triple Negative / Cytotoxics / Local Therapy, with 44% of respondents choosing this as an area of excitement
Only the top 7 tracks were chosen by more than 30% of physicians
Conclusions
Looking specifically at those tracks selected by more than 30% of the respondents, one gets the overall impression that the level of excitement is higher in the US than in other regions
Breast – Triple negative (TN) / Cytotoxics / Local Therapy was the only track selected by more than half of the respondents from any 1 region
Conclusions
As expected, those planning to attend the annual meeting in Chicago have a higher level of excitement than those not planning on attending
Combining all of the differences, there is about 20% more excitement for those planning to attend
Exceptions are the hematologic areas, perhaps due to the upcoming European Hematology Association (EHA) meeting in 2 weeks
Areas with the largest difference between planned attendees and not are central nervous system tumors (16% vs. 5%), non-prostate GU (35% vs. 11%), and patient and survivor care (16% vs. 8%) [analysis not shown]
Meet us in Chicago
Please visit our booth on the exhibit floor (booth 4043) to discuss this and other oncology research activities.
Immediately following the Annual meeting, we will conduct our annual series of MDOutlook OncoPolls, to assess the immediate impact of the meeting on clinical practice. We plan to compare the results with the aforementioned analysis to gauge how these pre-meeting expectations held up. Please look for this report in the near future. Click here to download a PDF copy of this post.
Contact us to discuss your oncology intelligence needs at [email protected] or +1.404.496.4136. And check out our new website. Thank you!
The National Cancer Moonshot Initiative, announced by President Obama in January, is gaining momentum. “We are at an inflection point, and the science is ready for the concerted new effort this initiative will deliver. Cancer is now known to be hundreds of diseases, each with unique features, driving forces, and vulnerabilities to treatments — and scientific understanding of how cancer develops and spreads has improved our ability to intervene and attack it”, President Obama stated in his 2016 State of the Union Address. You can access more information about the initiative and the initial announcement here.
At the upcoming ASCO meeting, on June 6 in Chicago, Vice-President Joe Biden will provide the professional cancer community an update to this Moonshot Initiative.
MDOutlook proudly exhibits at ASCO and will present its efforts and accomplishments in bringing deeper insights to the management of cancer. Please visit us at ASCO (booth 4043), or contact us by phone (+1.404.496.4136) / email to learn more.
MDOutlook® introduces excerpts from an MDOutlook’s OncoScape™: Patient Segmentation and Referral Patterns for Advanced Lung Cancer in the US.
This research is based on an on-line survey across multiple specialties, including oncologists, surgeons, primary care and emergency room physicians, that suspect and diagnose advanced lung cancer.
OncoScape Methodology
Primary research phase involved multiple surveys in the US to verified and validated medical oncologists, radiation oncologists, surgeons, pulmonologists, primary care physicians and emergency room physicians with an identified involvement in or suspicion of lung cancer utilizing targeting parameters
Fielded: 2014
Research via 45-minute interactive web-based survey instruments, utilizing proven MDOutlook methodology and proprietary technology
Response: 447 physicians across medical specialties from MDOutlook’s proprietary cancer panels
Patients were separated by prior treatment experience
Analysis and reporting by physician segmentation, treatment setting and patient segmentation
Commercialization Considerations: Importance of Patient Segmentation When Defining the Market Size
When developing complex forecasting models, patient demographics are often considered and epidemiological information collected in each market. The limitation to this approach is that epidemiological information does not equal market size. Not all patients will be considered as candidates for a particular therapy. Therefore, patient segmentation upfront is needed to adequately and informatively define the market size.
MDOutlook analysts performed a segmentation study to quantify the volume of the US market for patients in advanced (inoperable or metastatic) lung cancer who had not (yet) undergone any systemic therapy for the advanced disease. Patients with suspected or confirmed lung cancer were split into 3 staging groups key to our clients’ commercialization strategy:
“Treatment Naïve”– patients who initially present with advanced (inoperable or metastatic) disease and have never been diagnosed with or treated for any type of lung cancer
“Recurrent – No Prior Chemotherapy” – those who have been treated previously because of early (operable) lung cancer and whose disease has now recurred to an advanced (inoperable or metastatic) state. They did NOT receive any adjuvant chemotherapy as part of their treatment for early lung cancer
“Recurrent – Chemotherapy Experienced” – patients who have been treated previously because of early (operable) lung cancer and whose disease has now recurred to an advanced (inoperable or metastatic) state. As part of their treatment for early lung cancer, they received adjuvant chemotherapy. For this staging group, we asked respondents to consider patients who received their adjuvant chemotherapy from them or from another physician as being “NEW to you for advanced disease”
Conclusions
Over 60% of all patients diagnosed with advanced lung cancer present for the first time as inoperable or metastatic
A higher percentage of patients recur that did not have initial chemotherapy (21.8%) vs those that had prior chemotherapy (15.8%)
Small Cell Lung Cancer accounts for less than 15% of advanced lung cancer patients
The data was compared and mapped against data from other primary and secondary sources epidemiology to quantify the full U.S. market (data not shown)
Commercialization Considerations: Importance of Patient Referral Patterns when Developing Forecasts and Launch Strategies
Once the patient population is clearly defined and segmented, it’s equally important for forecasting and launch strategies to understand the costs that will be needed to reach the treating physicians of these patients. To accomplish this, an understanding of who is treating the patients when needs to be established. With referral patterns mapped out, a picture begins to develop of what it takes to reach and unlock the targeted patient population. This allows the dedication of defined commercialization resources in the most focused way.
MDOutlook analysts used the segmented patient populations to map the referral patterns from the time the patients were suspected of advanced lung cancer, through diagnosis and onto the treating physicians. There emerged important, major and sometimes subtler differences between patient segments, the diagnosis and subsequent management of patients. A rather striking example is shared below.
Conclusions
Patients suspected of, but not previously diagnosed with, advanced lung cancer are referred to community pulmonologists from multiple specialties
Once newly diagnosed with advanced lung cancer, the vast majority of patients, regardless of histology, are referred to medical oncologists for treatment
Conclusions
Suspected recurrent advanced lung cancer patients are predominantly referred to community pulmonologists from primary care physicians
In stark contrast to treatment naïve patients, community pulmonologists refer the majority of their diagnosed advanced lung cancer patients, who are recurrent without chemotherapy experience, to radiation oncologists for treatment
Impact on Your Commercialization Strategy
Building the commercialization strategy for new medicines or new indications is a daunting challenge, ever more so in oncology. Many factors, considerations and assumptions must be weighed and decided. Critical to any planning (and subsequent measurement of success) is reality-based market sizing and correctly quantified segmentation, including patients, physicians and treatment settings.
MDOutlook has supported many clients in doing exactly this using multi-channel intelligence assets and our proprietary panel of more than 95,000 cancer treaters. MDOutlook strengthens your commercialization efforts with primary research and actionable insights.
Strategic planning is a most critical aspect of managing a product or portfolio. Often there are gaps in the internal knowledge base to make important decisions. With our institutional knowledge of oncology, proprietary access to the largest global database of cancer treaters, and hundreds of oncology intelligence projects successfully delivered, we deliver insightful and useful answers on which you can immediately build your plan.
